Real-world use of an etanercept biosimilar including selective versus automatic substitution in inflammatory arthritis patients: a UK-based electronic health records study

OBJECTIVE: Biosimilars are approved as an alternative treatment to their originators. We compared the clinical outcomes of etanercept (ETN) biosimilar compared with ETN originator in real-world practice, from two local health boards in Wales with different policies on switching: automatic vs selecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooksey, Roxanne, Brophy, Sinead, Kennedy, Jonathan, Seaborne, Michael, Choy, Ernest
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336562/
https://www.ncbi.nlm.nih.gov/pubmed/35910710
http://dx.doi.org/10.1093/rap/rkac056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336562/
https://www.ncbi.nlm.nih.gov/pubmed/35910710
http://dx.doi.org/10.1093/rap/rkac056

Ejemplares similares